The ASAP Act: Medicare Coverage for Blood-Based Dementia Screening
November 20, 2025
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
Where This Stands
Currently in_committee. The next step in the legislative lifecycle is Floor Vote.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Finance Connection
| Candidate | Donor | Amount | Industry | Date |
|---|---|---|---|---|
| CATHERINE CORTEZ MASTO FOR SENATE | JONES, ROBERT | $1,500 | LIFE INSURANCE | Mar 2026 |
| CATHERINE CORTEZ MASTO FOR SENATE | THOMAS, LAUREN | $1,000 | CEO | Mar 2026 |
Reported financial relationships and timing signals. This does not prove motive or influence. Readers draw their own conclusions.
The Frame
This bill would change Medicare coverage rules to include blood-based dementia screening tests, potentially reducing out-of-pocket costs for Medicare beneficiaries seeking early detection of Alzheimer's starting January 1, 2028.
Potentially affected actors named in the source documents. Mention is not a position.
Medicare beneficiaries
Individuals enrolled in Medicare would gain access to coverage for specific blood-based dementia screening tests.
Diagnostic test manufacturers
Companies producing FDA-cleared blood-based dementia tests would be eligible for Medicare reimbursement for their products.
Current stage: in_committee.
Floor Vote.
Summary
Why It Matters
This bill would change Medicare coverage rules to include blood-based dementia screening tests, potentially reducing out-of-pocket costs for Medicare beneficiaries seeking early detection of Alzheimer's starting January 1, 2028.
Key Facts
- The bill mandates Medicare coverage for blood-based early detection screening tests for Alzheimer's and related dementias.
- Coverage is scheduled to begin on January 1, 2028.
- Eligible tests must be cleared, classified, or approved by the FDA under the Federal Food, Drug, and Cosmetic Act.
- Eligible tests include genomic sequencing blood tests or other equivalent tests (including single-analyte, cell-free nucleic acids, multiplex panels, or protein expression) as determined by the Secretary of Health and Human Services.
- The bill amends Section 1861 and Section 1833 of the Social Security Act to incorporate these tests into Medicare's payment and coverage framework.
Frequently Asked Questions
When would Medicare start covering these tests?
What kind of tests are covered?
News Coverage
Lobbying Activity
ACADIA PHARMACEUTICALS
2026
“Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.”
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Proactive Medicare Coverage
The bill sets a specific future date (2028) for coverage, suggesting a legislative intent to prepare the Medicare system for upcoming advancements in blood-based diagnostic technology.
Connected Entities
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz25Current news / social attention level
Publisher tools